Bora Completes Emergent Fill-Finish Facility Deal
Bora Pharmaceuticals has successfully completed the acquisition of a sterile fill-finish manufacturing facility in Baltimore-Camden, Maryland, from Emergent BioSolutions. The acquisition allows Bora to expand its manufacturing capabilities in the U.S., particularly in the production of sterile injectables, and complements its existing drug substance capabilities. The facility is equipped to handle a range of fill-finish services, which Bora says will enhance further.
Bora Pharmaceuticals Co., Ltd, a a global leader in pharmaceutical manufacturing, announced that it has completed the acquisition from Emergent BioSolutions of its sterile manufacturing facility in Baltimore-Camden, Maryland. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.
The newly acquired 87,000-sq. ft. facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services of vials and pre-filled syringes on four fill lines, lyophilization, formulation development, and support services.
“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO,” said Bobby Sheng, Chairman and CEO of Bora Group. “We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family.”
Bora completed the acquisition of Upsher-Smith Laboratories, the Minnesota-based generics manufacturer and marketer, in April 2024, adding oral dose capabilities at two facilities in Plymouth, MN and Maple Grove, MN. The Company’s extensive global CDMO network now includes ten high quality manufacturing facilities serving customers across dose forms and delivery technologies.
Gibson, Dunn & Crutcher LLP served as legal counsel to Bora in the acquisition.
For more, please find the original story source here.
